NCCN treatment guidelines

Pralsetinib is a NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)–recommended Treatment Option2,3

NCCN Guidelines® recommend pralsetinib (GAVRETO) as a Category 2A*:

lung circle icon

preferred first-line treatment option for RET fusion-positive metastatic NSCLC2*

thyroid circle icon

preferred treatment option for select patients with recurrent/persistent locoregional or distant metastatic RET mutation-positive MTC3

thyroid circle icon

systemic treatment option for structurally persistent/recurrent locoregional or distant metastatic RET fusion-positive PTC not amenable to RAI therapy3

*See the NCCN Guidelines for NSCLC and thyroid carcinoma for detailed recommendations, including other preferred options.
For locoregional, unresectable medullary thyroid cancer that is symptomatic or progressing by RECIST criteria; or for distantly metastatic disease that is symptomatic or progressive; or for distantly metastatic disease that is asymptomatic and unresectable or progressing by RECIST criteria.
NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
NSCLC=non–small cell lung cancer; MTC=medullary thyroid cancer; NCCN®=National Comprehensive Cancer Network®; PTC=papillary thyroid cancer; RAI=radioactive iodine; RECIST=Response Evaluation Criteria in Solid Tumors.